Compare Kinross Gold Corporation (KGC) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinross Gold Corporation vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Kinross Gold Corporation trades at $22.46 (market cap $27.68B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Kinross Gold Corporation is far larger — about 28.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Kinross Gold Corporation pays a 0.68% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kinross Gold Corporation for 53 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| KGC | MRVI | |
|---|---|---|
Market Cap | $27.68B | $972.90M |
Volume | 5,395,404 | 4,325,710 |
Sector | Basic Materials | Health |
52-Week High | $38.06 | $9.00 |
52-Week Low | $22.24 | $2.83 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | $25.76B | $1.08B |
Dividend Yield | 0.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinross Gold (KGC) trades at $23.44, down 0.47% on the day, amid a bearish technical signal despite strong fundamental performance. The company reported robust earnings beats in recent quarters with Q2 2026 EPS of $0.71 exceeding expectations, while revenue grew to $7.05 billion in 2025. However, recent news highlights production guidance cuts for 2026-2027 and ongoing legal investigations, creating mixed sentiment. Technical indicators show the stock trading near key support at $23 with RSI levels suggesting potential oversold conditions.
KGC presents a compelling value opportunity with attractive valuation multiples (P/E 8.91, EV/EBITDA 4.6) and strong profitability margins (net income margin 37.52%). The company's increasing cash flow generation and shareholder return framework support upside potential toward the $38.80 consensus price target. Key risks include production challenges at key mines, rising operating costs, and legal uncertainties that could pressure near-term performance despite the positive long-term gold price environment.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
